Replies to post #1875 on Palatin Technologies Inc. (PTN)

[Regis999]

IMHO more likely that PTN will do a JV on bremleanotide and use the cash flow to fund the other three PTN programs.

This looks like this could happen as they have spent $123.7 million on the other programs ((which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs) They are not going to just walk away on these programs. Dr. Spana is young enough to desire to continue the R&D effort on the three.

“Cumulative spending from inception to March 31, 2016 is approximately $224,500,000 on our bremelanotide program and approximately $123,700,000 on all our other programs (which include PL-3994, PL-8177, other melanocortin receptor agonists, obesity, other discovery programs and terminated programs).”